The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a "waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public", according to a report released by the Council of Europe.
The handling of the H1N1 pandemic by the World Health Organization (WHO), EU agencies and national governments led to a “waste of large sums of public money, and unjustified scares and fears about the health risks faced by the European public”, according to a report released by the Council of Europe. The report, prepared by UK MP Paul Flynn, identified evidence that the WHO had “vastly overrated” the seriousness of the situation, ultimately resulting in a distortion of public health priorities.
“This is a pandemic that never really was,” said Flynn, when presenting the report to the Social, Health and Family Affairs Committee of the Parliamentary Assembly of the Council of Europe.
The report is another blow to the WHO, which has been subject to a number of reviews and inquiries following its handling of the pandemic, which was declared on 11 June 2009.
One of Flynn’s particular concerns regarding the handling of the pandemic was the lack of transparency of the WHO’s decision-making processes and the possible influence of the pharmaceutical industry on some key decisions. This issue that has also been raised by a report produced in collaboration with the British Medical Journal (BMJ) and the Bureau of Investigative Journalism (The Bureau). According to this report, some experts advising the WHO had served as paid consultants to manufacturers of influenza drugs and vaccines; for instance, the report claims that key WHO guidance was authored by an influenza expert who had received payment for other work from Roche and GlaxoSmithKline, who manufacture Tamiflu and Relenza, respectively.
“The existence of these conflicts of interest is of grave concern, more so because the WHO has not been transparent about them,” said Fiona Godlee, Editor in Chief of the BMJ, in a statement.
The BMJ/The Bureau report concludes that the current system is “struggling to manage the inherent conflict between the pharmaceutical industry, WHO, and the global public health system”, and stresses that although planning for the worst is a sensible approach, there are “damaging issues” that must be addressed.”
Both reports believe that there should be greater transparency and better governance in public health, and both highlight the importance of rebuilding public confidence in health decisions taken by the WHO and European and national authorities. Flynn’s report includes a number of recommendations, including the “urgent” need for a thorough review of decisions taken by public health authorities during the H1N1 pandemic.
Godlee also believes that the decisions made during the pandemic must be evaluated “with full disclosure of the evidence behind the decisions, the names of those contributing to the decisions, and their conflicts of interest”.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.